Danielle Blake
Family · Detroit, MINPI 1144836701
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,880 of the $34,379 with a category attached, or 66.6%. GSK accounts for 87.5% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2024 at $20,148 and has fallen 61.0% since, to $7,863 in 2025. Among family clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 116 payments — averaging $296.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$30K
- Johnson & Johnson$918
- Beigene USA, Inc.$786
- Pfizer$469
- Takeda Pharmaceuticals U.S.A., Inc.$349
- Alnylam Pharmaceuticals Inc.$315
- plus $1K from 12 others
What the payments were for
- Consulting fees$3501%
- Speaking & faculty fees$22,88067%
- Travel & lodging$5,40716%
- Food & beverage$5,50416%
- Education$2391%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 52 | $30,084 |
| Johnson & Johnson | 9 | $918 |
| Beigene USA, Inc. | 7 | $786 |
| Pfizer | 8 | $469 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $349 |
| Alnylam Pharmaceuticals Inc. | 11 | $315 |
| Adaptive Biotechnologies Corporation | 2 | $291 |
| Amgen | 6 | $271 |
| Syndax Pharmaceuticals, Inc. | 6 | $153 |
| Jazz Pharmaceuticals Inc. | 2 | $144 |
| Genentech USA, Inc. | 1 | $139 |
| E.r. Squibb & Sons, L.L.C. | 1 | $130 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $123 |
| Astellas Pharma US Inc | 1 | $95 |
| Beone Medicines USA, Inc. | 2 | $39 |
| Gilead | 1 | $32 |
| Janssen Scientific Affairs, LLC | 1 | $28 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,379 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 79 | $1,255,368 |
| BrukinsaZanubrutinib | 72 | $985,385 |
| BosulifBosutinib | 51 | $549,857 |
| CalquenceAcalabrutinib Maleate | 40 | $528,335 |
| PomalystPomalidomide | 12 | $279,400 |
| SprycelDasatinib | 24 | $237,538 |
| JakafiRuxolitinib Phosphate | 12 | $194,786 |
| VenclextaVenetoclax | 22 | $177,421 |
| PegasysPeginterferon Alfa-2a | 12 | $50,512 |
| Imatinib Mesylate | 71 | $13,598 |
| ZarxioFilgrastim-Sndz | 11 | $13,236 |
| Cyclosporine ModifiedCyclosporine, Modified | 12 | $1,003 |
| Acyclovir | 45 | $744 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 21 | $388 |
| Fluconazole | 19 | $322 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $123 | $1,255,36879 claims |
| Beigene USA, Inc.Brukinsa | $786 | $985,38572 claims |
| PfizerBosulif | $469 | $549,85751 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $130 | $516,93736 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.
Other family in Detroit
- Elisheva EllenbergDetroit$150K
- Michelle ThomasDetroit$36K
- Lauren JuddDetroit$15K
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.